Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03370718 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
A Phase 2 study of Stage IV Adrenal Cortex Carcinoma AJCC v8 and Unresectable Adrenal Cortex Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03370718: Completed Phase 2 study of Stage IV Adrenal Cortex Carcinoma AJCC v8 and Unresectable Adrenal Cortex Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT03370718 is a Phase 2 study of Stage IV Adrenal Cortex Carcinoma AJCC v8 and Unresectable Adrenal Cortex Carcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03370718, a Phase 2 study of Stage IV Adrenal Cortex Carcinoma AJCC v8 and Unresectable Adrenal Cortex Carcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well cabozantinib works in treating patients with adrenal cortex cancer that has spread to nearby tissue, lymph nodes (locally advanced), or other places in the body (metastatic), and cannot be removed by surgery (unresectable). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
PFS rates will be monitored simultaneously using the Bayesian approach of Thall, Simon, Esty as extended by Thall and Sung. PFS is defined as no disease progression or death within the first 4 months of the proposed treatment.
Conditions Studied
Interventions
- DRUG Cabozantinib
- OTHER Pharmacokinetic Study
- OTHER Pharmacogenomic Study
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-02-26 |
| Est. Completion | 2024-01-12 |
| Phase | Phase 2 |
What the finished NCT03370718 record still lists
NCT03370718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Stage IV Adrenal Cortex Carcinoma AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.
NCT03370718 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03370718 about?
NCT03370718 is a clinical study titled "Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma". This phase II trial studies how well cabozantinib works in treating patients with adrenal cortex cancer that has spread to nearby tissue, lymph nodes (locally advanced), or other places in the body (metastatic), and cannot be removed by surgery (unresectable). Cabozantinib may stop the growth of tum...
What is the current status of trial NCT03370718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2018-02-26. Estimated completion is 2024-01-12.
What conditions does trial NCT03370718 study?
This clinical trial studies the following conditions: Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma, Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8.
What interventions are being tested in trial NCT03370718?
The interventions under investigation include: Cabozantinib (DRUG), Pharmacokinetic Study (OTHER), Pharmacogenomic Study (OTHER).
Who is sponsoring clinical trial NCT03370718?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03370718 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Adrenal Cortex Carcinoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03370718's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI